| VIRIDIAN THERAPEUTICS |
| USA |
| Gesundheit |
| US92790C1045 / A2QMUH |
| 1S1 (Frankfurt) / VRDN (NASDAQ) |
| FRA:1S1, ETR:1S1, 1S1:GR, NASDAQ:VRDN |
| - |
| https://www.viridianthera.. |
|
Viridian Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing best-in-class medicines for patients with autoimmune and rare diseases, particularly thyroid eye disease (TED). The compa..
>Volltext.. |
| 1736.35 Mio. EUR |
| 1235.84 Mio. EUR |
| 62.3 Mio. EUR |
| -337.87 Mio. EUR |
| -300.61 Mio. EUR |
| -3.31 EUR |
| 44.95 Mio. EUR |
| 154.91 Mio. EUR |
| -266.93 Mio. EUR |
| 14.71 |
| 21888.49% |
| -9.27% |
| - |
| - |
| - |
| - |
| VIRIDIAN |
| 29.06.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|